



Rodolphe Muñoz Legal Officer European Commission Unit B2 Cosmetics and Medical devices



## Aims of this presentation

#### To show the developments at the EU level of a UDI mechanism

#### To have your comments



## Important element

## The Recast elements, which will be presented, concern only the traceability aspects



## Content of the presentation

#### I. Introduction

II. The European Approach
III. The UDI System
A. Rationale
B. Definitions
C. One type of UDI
D. Database

#### IV. Other aspects

- A. Risk based approach
- B. Dynamic data
- C. Additional questions

#### V. Conclusion



## Introduction

# Historic developments US FDA GHTF (Ad Hoc WG on UDI) European Member States



## The EU Approach

#### Current status

#### Why a UDI now?

#### Recast and traceability





## Traceability for MDs at EU

## Current Status

- No traceability requirements at the EU level
- However, it is imposed at the Member States level
- And it is ensured by manufacturers



## Develop a EU UDI: Why now? Different reasons

- Safety and Internal market
- Recast of MD Directives First quarter 2012
- Obligation for Traceability in every future legislation (Decision 768/2008/EC)
- Work developed at the US and GHTF level



# Current status The last discussion with stakeholders and member States took place last week

- Political choices are mainly done



#### More "technical" work

- Impact Assessment
- Writing of the Directives
- Internal consultation



### Next steps

- COM Final
- Co-decision procedure
- (Parliament / Council)
- Adoption



- Transposition period
- Adoption of Delegated Acts



### Potential problems?

- Time
- Member States will develop their own national systems
- No traceability will be available
- Free movement will be hindered



## European Ad Hoc WG

#### First aims of this group

- Discuss GHTF documents
- Inform member States
- Take note of member States positions
- Present national systems


#### Additional aim

- Discuss the development of a Commission's Recommendation



## A Recommendation what for?

Adoption of the Recommendation



Adoption of detailed traceability requirements



#### The content of the Recommendation

#### GHTF Ad Hoc WG

- Main aspects
- Rationale
- Definitions
- « The » UDI System
- Database





## Rationale

#### Main purposes: Patient safety

- Improving tracking and tracing of devices
- Improving device recalls
- Improving adverse event reporting and surveillance
- Reducing medical errors
- Improving query in different database
- Fighting Counterfeits

#### Other purposes

- Better control of purchasing and distribution
- Stock management




## Definitions

#### UDI

- UDI system
- Static information
- Dynamic information

#### **UDI** Carrier / Placement






## European database

#### Internationally compatible

#### Merger with Eudamed





## Database attributes

#### Boolean choices

#### Numerical data

No free text as possible



## Database elements

## Vocabulary - If applicable - Optional



- 1. Device Identifier
- 2. Manufacturer Name (as represented on the label and/or instruction for use)
- 3. Manufacturer address structure
- 4. Contact Information (if different from manufacturer)
- 5. Nomenclature
- 6. Nomenclature term
- 7. Trade Name (Brand Name) if applicable
- 8. Device model number (or reference or catalogue number) if applicable
- 9. Controlled by: check all that apply
- 10. The Device Identifier can be found on (...)
- 11. In case of different levels of packaging, parent/child relationship shall be provided
- 12. Other alternative Device Identifiers (if applicable)
- **13**. Size, Volume, Length, Gauge, Diameter (if applicable)



- 14. Additional product Description (optional) 15. Storage and handling conditions (as labelled on the product and/or in the IFU)
- 16. Labelled as single use
- 17. Sterility
- 18. Restricted number of reuses (if applicable)
- **19. Labelled as Containing Latex**
- 20. Authorised Representatives (list of countries) (if required by the local / regional regulatory authority)
- 21. License or marketing authorization or registration number / code (if required by the local regulatory authority)
- 22. URL for additional information Web address (optional)
- 23. Critical Warnings or Contraindication (if applicable)



## Data attributes

## Questions

- The number of attributes
- The definition of attributes
- The necessary specificities

However the main question is: Why do we want a database?



## Data attributes

Consequences of "too much" data attributes
Burdensome
Costly

Therefore the rule shall be as a regulator before imposing one "data attribute": Why I need this attribute for?



## Data attributes


- Consequence of "not enough" attributes
- Necessity for regulators to request more attributes
- Obligation for manufacturers to fill out several databases

Therefore, it will be a useless database



### What is necessary to achieve...

#### MANUFACTURERS





## How to achieve the « ideal database » Involvement of every actors

- Regulators
- Manufacturers
- Distributors
- Hospital
- Doctors



## Other issues

#### Risk based approach

#### Dynamic information



Others aspects



## Risk based approach

#### All medical devices shall have:

- A static identifier
- A dynamic identifier

#### The difference will be:

- The type of dynamic data
- The placing of the UDI
- The time left to implement UDI obligations



## **Dynamic information**

- Legal obligation for all the supply chain
- Manufacturers
- Distributors
- Authorised representatives



## Conclusion

#### Next steps

- Written comments (End April 2011)
- GHTF ad Hoc UDI meeting (May 2011)

- Drafting of the Recommendation



# Thank you for your attention ...